Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.
Nausea and vomiting are two of the most common side-effects of anti-cancer treatment, and the discovery and clinical application of 5-hydroxytryptamine3 receptor antagonists has transformed the management of these side effects, resulting in a much improved quality of life for cancer patients. This text presents a detailed overview of the management of cancer-treatment induced emesis in a number of different treatment settings, and focuses on the mechanisms and use of 5-HT3 receptor antagonists. Contributions are also included from the points of view of the nurse and the patient.
Mario A. Dicato M.D. Department of Haematology-Oncology, Centre Hospitalier de Luxembourg.
1. The evolution of antiemetic treatment 2. Methodology of trials for treating nausea and vomiting 3. Pharmacology of serotonin and its receptors 4. Clinical aspects and prognostic factors of nausea and vomiting after chemotherapy 5. Platinum-induced acute nausea and vomiting 6. Platinum-induced delayed emesis 7. Treatment of moderately emetogenic chemotherapy-induced nausea and vomiting 8. Treatment of radiotherapy-induced nausea and vomiting 9. Prevention of nausea and vomiting in repeat courses 10. Anticipatory nausea and vomiting: models, mechanisms and management 11. Are there differences between 5-HT3 receptor antagonists? 12. Quality of life 13. Patients' point of view 14. Emesis: A challenge for nurses 15. Nausea and vomiting in children 16. Side-effects of antiemetics